Safety and Performance Study of the RELIANCE 4-Front Passive Fixation Lead

Boston Scientific Corporation167 enrolled

Overview

The objective of this study is to gather data to establish the chronic safety, performance and effectiveness of the RELIANCE 4-FRONT™ Passive Fixation Defibrillation Leads.

The RELIANCE 4-FRONT Passive Fixation Defibrillation Lead Post Market Clinical Follow-Up Study is a prospective, non-randomized, multi-center, single-group, post market clinical study to establish the chronic safety, performance and effectiveness of the RELIANCE 4-FRONT passive fixation defibrillation leads. A total of 167 patients (including 10 % attrition) are required to evaluate the Primary Endpoint. Up to 10 Investigational centers located in Europe and Israel. Lead-related Complication-Free Rate (CFR) from Implant through 3 Months Post-Implant. Lead-related complications associated with the RELIANCE 4-FRONT passive fixation lead will count toward this endpoint. Lead-related Complication-Free Rate from 3 Months through 15 Months Post-Implant. Lead-related complications associated with the RELIANCE 4-FRONT passive fixation lead will count toward this endpoint. * Lead-related Complication-Free Rate from 3 Months through 24 Months Post-Implant * Pacing Threshold at 0.5 ms pulse width at 3 Months Post-Implant * Sensed Amplitude at 3 Months Post-Implant * Pacing Impedance at 3 Months Post-Implant All endpoints will be assessed for the RELIANCE 4-FRONT passive fixation lead. Clinic visits will occur at: * Enrollment Visit (no later than 30 days prior to implant procedure) * Implant Procedure (Day 0; all future follow ups based on this date) * Pre-Discharge Clinic Visit (3 - 72 hours post-implant) * One Month Clinic Visit (30±7 days) * 3 Month Clinic Visit (91 ± 21 days) * 6 Month Clinic Visit (180 ± 30 days) * 12 Month Clinic Visit (365 ± 45 days) * 18 Month Clinic Visit (545± 45 days) * 24 Month Clinic Visit (730 ± 45 days) The study will be considered completed after all subjects have completed the 24 Month follow-up and study completion is anticipated in 2015. Primary endpoint completion is anticipated after all subjects have completed the 3 Month follow-up visit. All study required visits will be completed during clinic visits. Hypotheses testing in the RELIANCE 4-FRONT passive fixation PMCF Study will use standard statistical methodology as specified more in detail in the protocol.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

167

Conditions

Tachycardia Ventricular Fibrillation Ventricular Flutter

Interventions

RELIANCE 4-FRONT™ Passive Fixation lead implantationDEVICE

Implantation of transvenous defibrillation lead with passive fixation mechanism.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Willing and capable of providing informed consent * Has an indication for implantation of a single or dual chamber ICD or CRT-D system in their respective geography * Subjects planned to be implanted with the RELIANCE 4-FRONT Passive Fixation Lead * Willing and capable of participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol * Age 18 or above, or of legal age to give informed consent specific to state and national law Exclusion Criteria: * Known or suspected sensitivity to Dexamethasone Acetate (DXA) * Mechanical tricuspid heart valve * Subject is enrolled in any other concurrent study without prior written approval from Boston Scientific (BSC), with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict and do not affect the following: * Schedule of procedures for the RELIANCE 4-Front Study (i.e. should not cause additional or missed visits); * RELIANCE 4-Front Study outcome (i.e. involve medications that could affect the heart rate of the subject); * Conduct of the RELIANCE 4-Front Study per Good Clinical Practice (GCP)/ International Organization for Standardization (ISO) 14155:2011/ 21 CFR 812/ local regulations * Currently on the active heart transplant list * Documented life expectancy of less than 12 months * Women of childbearing potential who are or might be pregnant at the time of study enrollment (method of assessment upon physician discretion) * Currently requiring chronic dialysis

Locations (11)

German Heart Center

Berlin, Germany

Meir Medical Center

Kfar Saba, Israel

Beilinson Medical Center

Petah Tikva, Israel

Sheba Medical Center

Outcomes

Primary Outcomes

Complication Free Rate

Lead-related Complication-Free Rate (CFR) from Implant through 3 Months Post-Implant.

Time frame: 3-months

Secondary Outcomes

Complication Free Rate

Lead-related Complication-Free Rate from 3 Months through 15 Months Post-Implant.

Time frame: 3 months through 15 months post implant

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.